Dundar H Z, Aksoy F, Aksoy S Ak, Tasar P, Ugras N, Tunca B, Egeli U, Cecener G, Yerci O, Kaya E
General Surgery, Uludag University, Bursa, Turkey.
Medical Biology, Uludag University, Bursa, Turkey.
Transplant Proc. 2019 May;51(4):1157-1161. doi: 10.1016/j.transproceed.2019.01.089. Epub 2019 Feb 8.
Liver transplantation (LT) is the best treatment option for hepatitis B virus (HBV)-mediated hepatocellular carcinoma (HCC). Nevertheless, recurrence is the most important issue after LT. The aims of the present study were to evaluate the relation of dysregulated expression of microRNAs (miRNAs) in recurrence formation in HBV-mediated HCC cases. A total of 42 HBV-mediated HCC patients were evaluated in this study. Among 21 miRNAs, the expression level of miR-106a and miR-21 were higher and miR-143 and miR145 were lower in patients with HCC compared with noncancerous liver tissues (P = .0388, P = .0214, P = .0321, and P = .002, respectively). Compared with nonrecurrent patients, the expression level of miR-21 was 3.54-fold higher and miR-145 was 2.42-fold lower in patients with recurrence during the 5-year follow-up (P = .004 and P = .032; respectively). In addition, according to multivariate Cox regression analysis, the overexpression of miR-21 was found to be a prognostic indicator in HBV-mediated HCC patients (P = .002). In conclusion, we show a significant association between high expression of miR-21 and recurrence in HBV-mediated HCC. Therefore, up-regulation of miR-21 could serve as a promising prognostic marker for HCC.
肝移植(LT)是治疗乙型肝炎病毒(HBV)介导的肝细胞癌(HCC)的最佳选择。然而,复发是肝移植后最重要的问题。本研究的目的是评估HBV介导的HCC病例中微小RNA(miRNA)表达失调与复发形成之间的关系。本研究共评估了42例HBV介导的HCC患者。在21种miRNA中,与非癌肝组织相比,HCC患者中miR-106a和miR-21的表达水平较高,而miR-143和miR-145的表达水平较低(P分别为0.0388、0.0214、0.0321和0.002)。与未复发患者相比,在5年随访期间复发患者中miR-21的表达水平高3.54倍,miR-145的表达水平低2.42倍(P分别为0.004和0.032)。此外,根据多变量Cox回归分析,发现miR-21的过表达是HBV介导的HCC患者的一个预后指标(P = 0.002)。总之,我们发现miR-21的高表达与HBV介导的HCC复发之间存在显著关联。因此,miR-21的上调可能成为HCC一个有前景的预后标志物。